Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2016

View Archived Issues

GnHR antagonist SKI-2670 well tolerated, suppresses hormones in phase I trial

Sirenas enters drug discovery collaboration with Calibr

U.K. Dstl gets funding to study inhaled ciprofloxacin in biodefense

Two mutations at the same anticodon stem pair may cause different myopathic phenotypes

Hookipa Biotech presents data on CMV vaccine candidate

PSMA ligand [99mTc]MIP-1427 improves diagnostics in osseous metastasized prostate cancer

Argonaut Therapeutics raises funds to develop cancer drugs

Advanced Proteome Therapeutics acquires option to antibody candidates from University of Toronto

Pfizer wins grant from Bill & Melinda Gates Foundation for GBS vaccine trial

Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder

Merck & Co. patents TrK-A inhibitors

Shionogi discloses ACC2 inhibitors

FDA grants accelerated approval for Lartruvo in soft tissue sarcoma

Takeda Pharmaceutical describes ACC1 inhibitors

Fujifilm Kyowa Kirin Biologics reports phase III results for adalimumab biosimilar FKB-327

Spotlight Innovation obtains exclusive worldwide license for STL-182

ICGEB and Sun Pharma collaborate on new tetravalent dengue vaccine

Pivotal phase III study of letermovir meets primary endpoint

Texas A&M University develops pateamine A analogues

Incyte presents LSD1 inhibitors

MHRA accepts XOMA's proposal for phase II study of XOMA-358 in congenital hyperinsulinism

Cerulean collaborates with Novartis to develop nanoparticle-drug conjugate product candidates

Rare SHANK3 mutation may be a risk factor for ASD and schizophrenia

Applied Genetic Technologies files IND for second achromatopsia therapeutic candidate

Australian NHMRC funds research in chronic lung diseases

Perlara forms drug discovery collaboration with Novartis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...